Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Closed Meeting, 69642 [2012-28159]
Download as PDF
<![CDATA[
69642
Federal Register / Vol. 77, No. 224 / Tuesday, November 20, 2012 / Notices
Scientific Review, Eunice Kennedy Shriver
National Institute of Child Health and
Human Development, NIH, 6100 Executive
Blvd., Room 5B01, Rockville, MD 20852,
301–435–6973, David.Weinberg@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.864, Population Research;
93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation
Research; 93.209, Contraception and
Infertility Loan Repayment Program, National
Institutes of Health, HHS)
Dated: November 14, 2012.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2012–28161 Filed 11–19–12; 8:45 am]
National Institutes of Health
Eunice Kennedy Shriver National
Institute of Child Health & Human
Development; Notice of Closed
Meeting
wreier-aviles on DSK5TPTVN1PROD with
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice.
AGENCY:
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Child Health and Human Development
Special Emphasis Panel; ‘‘Biomedical/
Biobehavioral Research Administration
Development (BRAD) Award (G11).’’
Date: November 29, 2012.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6100
Executive Boulevard, Rockville, MD 20852
(Telephone Conference).
Contact Person: Anne Krey, Ph.D.,
Scientific Review Officer, Division of
Scientific Review, Eunice Kennedy Shriver
National Institute of Child Health And
Human Development, NIH, 6100 Executive
Blvd., Room 5B01, Bethesda, MD 20892,
301–435–6908, ak41o@nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.864, Population Research;
Jkt 229001
[FR Doc. 2012–28159 Filed 11–19–12; 8:45 am]
Current List of Laboratories and
Instrumented Initial Testing Facilities
Which Meet Minimum Standards To
Engage in Urine Drug Testing for
Federal Agencies
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
15:12 Nov 19, 2012
Dated: November 13, 2012.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
Substance Abuse and Mental Health
Services Administration
BILLING CODE 4140–01–P
VerDate Mar<15>2010
93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation
Research; 93.209, Contraception and
Infertility Loan Repayment Program, National
Institutes of Health, HHS)
The Department of Health and
Human Services (HHS) notifies Federal
agencies of the Laboratories and
Instrumented Initial Testing Facilities
(IITF) currently certified to meet the
standards of the Mandatory Guidelines
for Federal Workplace Drug Testing
Programs (Mandatory Guidelines). The
Mandatory Guidelines were first
published in the Federal Register on
April 11, 1988 (53 FR 11970), and
subsequently revised in the Federal
Register on June 9, 1994 (59 FR 29908);
September 30, 1997 (62 FR 51118);
April 13, 2004 (69 FR 19644); November
25, 2008 (73 FR 71858); December 10,
2008 (73 FR 75122); and on April 30,
2010 (75 FR 22809).
A notice listing all currently certified
Laboratories and Instrumented Initial
Testing Facilities (IITF) is published in
the Federal Register during the first
week of each month. If any Laboratory/
IITF’s certification is suspended or
revoked, the Laboratory/IITF will be
omitted from subsequent lists until such
time as it is restored to full certification
under the Mandatory Guidelines.
If any Laboratory/IITF has withdrawn
from the HHS National Laboratory
Certification Program (NLCP) during the
past month, it will be listed at the end
and will be omitted from the monthly
listing thereafter.
This notice is also available on the
Internet at https://
www.workplace.samhsa.gov and https://
www.drugfreeworkplace.gov.
SUMMARY:
Mrs.
Giselle Hersh, Division of Workplace
FOR FURTHER INFORMATION CONTACT:
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
Programs, SAMHSA/CSAP, Room 2–
1042, One Choke Cherry Road,
Rockville, Maryland 20857; 240–276–
2600 (voice), 240–276–2610 (fax).
SUPPLEMENTARY INFORMATION: The
Mandatory Guidelines were initially
developed in accordance with Executive
Order 12564 and section 503 of Public
Law 100–71. The ‘‘Mandatory
Guidelines for Federal Workplace Drug
Testing Programs’’, as amended in the
revisions listed above, requires strict
standards that Laboratories and
Instrumented Initial Testing Facilities
(IITF) must meet in order to conduct
drug and specimen validity tests on
urine specimens for Federal agencies.
To become certified, an applicant
Laboratory/IITF must undergo three
rounds of performance testing plus an
on-site inspection. To maintain that
certification, a Laboratory/IITF must
participate in a quarterly performance
testing program plus undergo periodic,
on-site inspections.
Laboratories and Instrumented Initial
Testing Facilities (IITF) in the applicant
stage of certification are not to be
considered as meeting the minimum
requirements described in the HHS
Mandatory Guidelines. A Laboratory/
IITF must have its letter of certification
from HHS/SAMHSA (formerly: HHS/
NIDA) which attests that it has met
minimum standards.
In accordance with the Mandatory
Guidelines dated November 25, 2008
(73 FR 71858), the following
Laboratories and Instrumented Initial
Testing Facilities (IITF) meet the
minimum standards to conduct drug
and specimen validity tests on urine
specimens:
Instrumented Initial Testing Facilities
(IITF)
None.
Laboratories
ACL Laboratories, 8901 W. Lincoln Ave.,
West Allis, WI 53227, 414–328–7840/800–
877–7016. (Formerly: Bayshore Clinical
Laboratory.)
ACM Medical Laboratory, Inc., 160 Elmgrove
Park, Rochester, NY 14624, 585–429–2264.
Advanced Toxicology Network, 3560 Air
Center Cove, Suite 101, Memphis, TN
38118, 901–794–5770/888–290–1150.
Aegis Analytical Laboratories, 345 Hill Ave.,
Nashville, TN 37210, 615–255–2400.
(Formerly: Aegis Sciences Corporation,
Aegis Analytical Laboratories, Inc.).
Alere Toxicology Services, 1111 Newton St.,
Gretna, LA 70053, 504–361–8989/800–
433–3823. (Formerly: Kroll Laboratory
Specialists, Inc., Laboratory Specialists,
Inc.)
Alere Toxicology Services, 450 Southlake
Blvd., Richmond, VA 23236, 804–378–
9130. (Formerly: Kroll Laboratory
Specialists, Inc., Scientific Testing
E:\FR\FM\20NON1.SGM
20NON1
]]>Agencies
[Federal Register Volume 77, Number 224 (Tuesday, November 20, 2012)]
[Notices]
[Page 69642]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-28159]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Eunice Kennedy Shriver National Institute of Child Health & Human
Development; Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Child Health and Human
Development Special Emphasis Panel; ``Biomedical/Biobehavioral
Research Administration Development (BRAD) Award (G11).''
Date: November 29, 2012.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6100 Executive Boulevard,
Rockville, MD 20852 (Telephone Conference).
Contact Person: Anne Krey, Ph.D., Scientific Review Officer,
Division of Scientific Review, Eunice Kennedy Shriver National
Institute of Child Health And Human Development, NIH, 6100 Executive
Blvd., Room 5B01, Bethesda, MD 20892, 301-435-6908, ak41o@nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance Program Nos. 93.864,
Population Research; 93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation Research; 93.209,
Contraception and Infertility Loan Repayment Program, National
Institutes of Health, HHS)
Dated: November 13, 2012.
Michelle Trout,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2012-28159 Filed 11-19-12; 8:45 am]
BILLING CODE 4140-01-P
